Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We identified five hepatoblastomas informative for a transcribed polymorphism of the IGF2 gene.
|
7728748 |
1995 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Previous reports have demonstrated that expression of insulin-like growth factor 2 (IGF2) is altered in hepatoblastoma.
|
10789725 |
2000 |
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
H19 and IGF-2 allele-specific expression in hepatoblastoma.
|
10732739 |
2000 |
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that H19 may play a role as a common imprinted tumor suppressor gene in "sporadic" hepatoblastomas but may at times work independently of IGF2 expression.
|
10404060 |
1999 |
Hepatoblastoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Using luciferase reporter assays, we demonstrated that PLAG1 transactivates transcription from the embryonic IGF2 promoter P3, also in hepatoblastoma cell lines.
|
14695992 |
2004 |
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma.
|
14695992 |
2004 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting.
|
7624139 |
1995 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
RGD |
Changes in the antioxidant defense and hepatic drug metabolizing enzyme and isoenzyme levels, 8-hydroxydeoxyguanosine formation and expressions of c-raf.1 and insulin-like growth factor II genes during the stages of development of hepatocellular carcinoma in rats.
|
17554210 |
2007 |
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Therefore, abnormal methylation was found to be correlated with altered regulation of igf2 and h19 expression in human hepatoblastoma and may be involved in the genesis of this tumor.
|
9462704 |
1998 |
Hepatoblastoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
In this study an intragenic ApaI polymorphism is used to examine imprinting of the insulin-like growth factor II gene in hepatoblastoma.
|
8402661 |
1993 |
Hepatoblastoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Here, we have used bisulfite genomic sequencing to characterize the methylation pattern of the IGF2 promoter P3 in the hepatoblastoma-derived cell line Hep T1, in the original tumor from which Hep T1 is derived, and in nude mouse xenografts of the Hep T1 cell line.
|
11597130 |
2001 |
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In the present study, in order to investigate IGF2 gene imprinting status at the cellular level, allelic analysis was performed of IGF2 gene expression transcribed from the P1 and P3 promoters, using reverse transcription polymerase chain reaction (RT-PCR) on human fetal liver and hepatoblastoma.
|
9713365 |
1998 |
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
IGF2 mRNA expression was increased in 11 of 12 HB samples.
|
11021841 |
2000 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Azathioprine desensitizes liver cancer cells to insulin-like growth factor 1 and causes apoptosis when it is combined with bafilomycin A1.
|
23958494 |
2013 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We studied the activation status of the Wnt and Notch pathways and the differential expression of hepatocyte nuclear factor 4alpha, EGFR, and IGF2 genes, relevant to liver development and malignant transformation in histologic variants of hepatoblastoma.
|
19200579 |
2009 |
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Increased IGF2 expression with predominant embryonic P3 transcript was found in the majority of HBs with ROI and foetal livers.
|
19034281 |
2008 |
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The data suggested that IGF2 and IGFBP2 gene expression could be regarded as a marker for assessment of the degree of differentiation in hepatoblastoma.
|
7543440 |
1995 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma.
|
17072986 |
2006 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We and others have previously shown that the overexpression of insulin-like growth factor 2 (IGF2), loss of imprinting at the IGF2/H19 locus, and amplification of pleomorphic adenoma gene 1 (PLAG1) are common features in HB, suggesting a critical role of the IGF axis in hepatoblastomagenesis.
|
22401581 |
2012 |